Technology Networks - Multiple Sclerosis Market Forecast

OVERVIEW
- Summary
OVERVIEW
- This product contains forecasts for multiple sclerosis drugs across the seven major markets from 2011 to 2020. It has been designed for delivery in an excel data pack format, but for more detail about multiple sclerosis please see the accompanying Market and Product Forecasts: Multiple sclerosis word document and PowerPoint executive presentation (HC00055-003).
  - The associated report and PowerPoint presentation can be found under Latest research in the Knowledge centre, through the search function or by contacting your sales representative.
  - Please select the data pack option from the download menu at the side of the page to access the model.
  - Introduction
  - Using a patient-based methodology, Datamonitor estimates that sales of multiple sclerosis drugs across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) will total $8.6bn in 2011. With new more efficacious and convenient product launches from a dynamic pipeline this market is expected to expand to $10.1bn in 2020, growing with a compound annual growth rate (CAGR) of 1.7%.
  - Features and benefits
  - Research and analysis highlights
  - Key questions answered
- Forecasting methodology
  - Volume and value forecast methodology
  - Price and compliance assumptions
- Disclaimer
FIGURES
- Figure: Patient-based forecast methodology for Alzheimer’s disease, 2011

Multiple Sclerosis Market Forecast